FDA Advisory Committee Conflict Policy Takes A Toll; Chairs Plan Response
Executive Summary
Cardiovascular & Renal Drugs Advisory Committee Chair William Hiatt plans to write an editorial concerning the need for a more transparent conflict of interest policy for panel members